Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.71 |
| ▸ | ABL1 | P00519 | 11/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.47 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22392156 | 0.89 | ADORA3 (0.57) | AHRSCN2ASCN10AADORA3CFTR | |
| SCHEMBL22429411 | 0.87 | AHR (0.54) | AHRABL1ADORA3KDR | |
| SCHEMBL25580526 | 0.86 | AHR (0.53) | AHRABL1SCN2ASCN10AADORA3 | |
| SCHEMBL21001328 | 0.86 | AHR (0.53) | AHRABL1SCN2ASCN10AADORA3 | |
| SCHEMBL22391987 | 0.86 | AHR (0.53) | AHRABL1SCN2ASCN10AADORA3 | |
| SCHEMBL22392101 | 0.85 | ADORA3 (0.53) | AHRSCN2ASCN10AADORA3CFTR | |
| SCHEMBL21001326 | 0.85 | ADORA3 (0.53) | AHRSCN2ASCN10AADORA3CFTR | |
| SCHEMBL21001725 | 0.85 | AHR (0.52) | AHRSCN2ASCN10A | |
| SCHEMBL25580216 | 0.85 | AHR (0.69) | AHRABL1OPRM1KCNH2CYP11B1 | |
| SCHEMBL22430223 | 0.85 | AHR (0.54) | AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3713926-B1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AG (DE) | 2023-06-07 | — | — | EP | claimed |
| US-11304946-B2 | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2022-04-19 | — | — | US | claimed |
| US-20200289509-A1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-17 | — | — | US | claimed |
| EP-3713926-B1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AG (DE) | 2023-06-07 | — | — | EP | disclosed |
| EP-3713926-B1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AG (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-11304946-B2 | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2022-04-19 | — | — | US | disclosed |
| US-11304946-B2 | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2022-04-19 | — | — | US | disclosed |
| EP-3713926-A1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | Bayer Aktiengesellschaft (DE) | 2020-09-30 | — | — | EP | disclosed |
| US-20200289509-A1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-17 | — | — | US | disclosed |
| US-20200289509-A1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-17 | — | — | US | disclosed |
| WO-2019101641-A1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289509-A1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | AHR, ARNT, HRH2 | AHR 1/4885ABL1 496/4885OPRM1 531/4885 |
| US-11304946-B2 | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | AHR, ARNT, HRH2 | AHR 1/4885ABL1 665/4885OPRM1 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.